RephImmune 

RephImmune focuses on innovation in cell and gene therapy, committed to tackling the challenges of solid tumors. Our proprietary regenerative biology platform has enabled the development of a next-generation cell therapy engine, RACE (Reconstitute-Immunity Antigen-Cell Engager), demonstrating transformative potential.

RACE overcomes the limitations of conventional cell therapies, redefining how immune cells can be harnessed. Preclinical data highlight its strong advantages, opening new possibilities in tumor treatment.

Our mission is to lead the next generation of solid tumor cell therapies and bring hope to more cancer patients. Join us in redefining the future of cancer treatment. 

Interested in Learning More?